Introduction
Hepatitis B virus (HBV) infection constitutes a worldwide public health problem, causing both acute and chronic liver infections. The acute infection results in symptoms of varying severity, including fever, malaise and jaundice, and resolves spontaneously in most patients within 6 months. However, a proportion of patients become chronic carriers ofHBV. Chronic carriers may be largely asymptomatic but remain infectious and therefore constitute a pool of infectivity in the community. Other patients with chronic active hepatitis develop severe symptoms including persistent malaise and fatigue, enlarged liver and spleen, and gastrointestinal bleeding. There are an estimated 350 million chronic carriers of the virus worldwide, many of whom develop cirrhosis and hepatocellular carcinoma (Locarnini & Gust, 1988; Kane 1995) .
One of the major problems in dealing with HBV is breaking the cycle of infection that stems from the existence of chronic carriers of the virus. The viral infection is passed from the mothers who are chronic carriers to their babies, who in turn become chronically infected (Locarnini & Gust, 1988) . The age of infection is important in determining carrier status. Chronic infection is the norm when infection occurs in infants, but becomes less frequent with increasing age of initial infection (Lok, 1992) . Of the estimated 350 million chronic carriers worldwide, 1-2% die each year from complications associated with the infection. The majority of these deaths are in developing countries, and occur from cirrhosis of the liver and hepatocellular carcinoma.
HBV infection can be prevented by vaccination. The vaccine was originally produced from HBV surface antigen (Maupas et al., 1976; Szmuness et al., 1981) , purified from the plasma of infected carriers. However, current vaccines now use proteins prepared from recombinant DNA vectors (McAleer et al., 1984) . Vaccination is effective, although the response decreases in older adults (Zajac et al., 1986) , so booster doses are often recommended (Zuckerman 1996) . Another minor problem with the vaccine is that it L..========i Envelopment===========.J @' export HBV enters the cell and uncoats in the cytoplasm. Virion DNA (putatively still in the nucleocapsid) is translocated to the nucleus where it forms a fully double-stranded supercoiled (SC) or CCC DNA. The CCC DNA acts as the transcriptional template from which a number of transcripts are produced, the largest of which is a 3.5 kb pregenome RNA. The pregenome RNA and the viral polymerase protein are encapsidated into immature core particles in the cytoplasm and viral DNA is generated by a complex process of reverse transcription followed by DNA synthesis. The mature core particles can be utilized by two different pathways. The core particles can associate with the envelope proteins to produce virions or, as part of a regulatory pathway, they may be recycled back to the nucleus to help maintain the pool of CCC DNA molecules. Production of HBV DNA, RNA and various viral proteins can be monitored by Southern, Northern and Western blot techniques. and their incorporation into nascent DNA either inhibits further chain elongation or results in functionally impaired products (Shaw & Locarnini, 1995) .
The existence of two animal models for hepatitis B infection, the woodchuck (Summers et al., 1978) and the duck (Mason et al., 1980) , has allowed researchers to study the lifecycle of HBV and to evaluate the effectiveness of nucleoside analogues against HBY. In these two models there are both virus-free populations, which allow acute infections to be studied, and populations in which the virus is maternally transmitted, so chronic infections can be investigated. The initial studies that elucidated the lifecycle of the HBV were performed using the duck model (Summers & Mason, 1982) . Primary hepatocycte cultures can also be derived from the livers of ducks infected with duck HBV (DHBV). This system allows potential antiviral compounds to be screened in vitro. Promising candidates can then be tested in vivo. 
Nucleoside analogues
Nucleoside analogues are currently being investigated as potential anti-HBV agents. Initial indications that these compounds could be effective came from research published in 1989 (Locarnini et al., 1989) . Two human immunodeficiency virus (HIV)-infected patients were treated for cytomegalovirus (CMV) retinitis with the nucleoside analogue, ganciclovir. Both patients were also chronic HBV carriers, so the levels of HBV DNA in the blood were monitored to investigate the effects of ganciclovir on the virus. The amount of HBV DNA in both patients fell within a few days of starting the treatment, and was below detectable levels after 1 week of therapy. However, a followup test on one of the patients after a period off ganciclovir therapy revealed that HBV DNA had returned to pretreatment values.
Most antiviral nucleoside analogues are active only after intracellular activation to the corresponding triphosphates. Nucleoside analogues are already used to treat herpesvirus infections, but herpesviruses differ from HBV in that they encode enzymes that are required for analogue activation. To be effective in HBV-infected cells, nucleoside analogues such as penciclovir and aciclovir must be activated by cellular enzymes. Intracellular analogue triphosphates compete with their natural counterparts for nucleic acid polymerases, has been associated with escape mutants in young children. If the vaccination occurs just before or just after HBV infection, then stimulation of the immune response by the vaccine may allow the virus to mutate, permitting viral replication to continue (Thomas, 1995) .
A more significant problem with the vaccine involves the logistics and resources required to perform mass immunization programmes. In particular there is a need for education about the benefits of vaccinating children. In addition, the vaccine is ineffective against chronic carriers of the disease. Thus, although the vaccine is effective in preventing HBV infection, the existence of chronic carriers means that there is also a clear need for effective antiviral therapy.
Alpha interferon was the first effective therapeutic agent used to treat hepatitis B (Greenberg et al., 1976; Perillo, 1989) . This agent is effective in eliminating hepatitis B infection in 30-40% of patients, but is associated with significant toxicity (Alexander et al., 1987; Brook et al., 1989) . In addition, alpha interferon is only effective in certain types of patients (e.g. patients infected as an adult, patients with evidence of an adequate immune response to hepatitis B, patients with low virus levels in the plasma, and patients without liver cirrhosis (Brook et al., 1989; Lok, 1994) . Unfortunately, these are not the characteristics of many chronic HBV carriers, so alternative therapies need to be investigated. the 10-day treatment in six of 11 evaluable patients, whereas the placebo had no effect (Fig. 2) . However, virus levels recovered once therapy was discontinued, suggesting that prolonged therapy may be necessary.
The effects of a longer, 16-week treatment with famciclovir were investigated in a multicentre, Phase lIB study (Trepo et al., 1996) . Three doses of famciclovir, 125 mg, 250 mg or 500 mg three times daily, were compared with a placebo in 333 patients with chronic HBV infection. All doses of famciclovir produced a rapid, dose-dependent reduction of HBV DNA levels in the blood. These reductions were significant within 1 week of treatment (P < 0.0001), and lasted throughout the treatment period. Famciclovir treatment also significandy reduced levels of alanine aminotransferase (ALT), at all doses, within 8 weeks of starting therapy. In patients treated with 500 mg three times daily doses of famciclovir, the reductions in both HBV DNA and ALT levels persisted to the end of the 8-month, treatment-free follow-up period. In addition, this treatment group showed significant increases in HBe seroconversion, compared with the placebo group (P = 0.04). Thus, short-term therapy with famciclovir may have prolonged effects in patients.
Famciclovir was well tolerated in both studies. No reports of toxicity or hepatic decompensation arising from the cessation of treatment have been reported. Lamivudine is generally well tolerated, however, a certain proportion of individuals may experience a hepatitic flare or rebound upon cessation of therapy; In a study published in 1995, Schalm's group (Honkoop et al., 1995) reported on a case of HBV reactivation after lamivudine withdrawal. One patient anecdotally experienced a nearly 100-times rise in ALT levels, 4 months after completion of treatment.
Adapted from Main et al., (1996) Two nucleoside analogues are currently undergoing Phase III clinical trials for anti-hepatitis B treatment. These are famciclovir, the prodrug for the guanine nucleoside analogue, penciclovir and lamivudine, a cytosine nucleoside analogue. In one study (Main et al., 1996) the effects of famciclovir, 250 mg or 500 mg three times daily, on HEV were compared with a placebo. Both famciclovir doses decreased the levels of viral DNA in the blood dramatically during
Clinical studies with nucleoside analogues
HBV is a hepadnavirus, and has a relatively small DNA genome. The two DNA strands associate to form a circular, partially double-stranded molecule, which is converted to a fully double-stranded molecule on infection (Fig. 1) . This closed circular DNA molecule is supercoiled, making it a readily identifiable intermediate in the viral replication process. Viral replication proceeds by the generation of a 3.5 kb RNA transcript, known as the pregenome molecule. Multiple copies of this molecule are produced, and are then packaged into the core protein coat. The DNA genome is then generated by reverse transcription of the RNA strand, followed by conventional synthesis of the second DNA strand. The DNA, RNA and protein molecules produced at different stages of the virallifecycle can all be analysed by Southern, Northern and Western blot hybridizations, respectively. This allows the site of action of an antiviral agent within the infected hepatocyte to be determined.
The duck model has been used to study the antiviral effects of penciclovir, the active metabolite derived from famciclovir. In the initial studies DHBVinfected ducks were treated with penciclovir for a period of 4 weeks. The levels of viral DNA in the blood were analysed during the treatment phase, and in the 4 weeks following treatment. During treatment, the viral DNA levels fell dramatically. However, at the end of the treatment period there was a relapse, and viral DNA returned to pretreatment levels. When the amount of supercoiled DNA intermediate present in the liver was analysed, levels were found to be unaffected by the treatment.
The effects of long-term treatment with penciclovir were then assessed . The compound was given for 6 months, and the amount of viral DNA in the blood was again examined. As in the previous study, the levels of DNA in the blood decreased during therapy, becoming undetectable. However, the supercoiled intermediate was still present in the liver, although its levels did decrease over time. The failure to eradicate this intermediate means that once treatment is stopped, the virus can proliferate. This can be followed by measuring viral DNA, RNA and protein markers, which are all suppressed during therapy, but return to pretreatment levels once therapy is stopped.
Whereas these flares may occur in some patients regardless of antiviral intervention, it is estimated that some elevation in hepatic enzyme activity may occur in up to 20% of lamivudine-treated individuals.
One explanation put forward to explain this sudden surge in hepatic activity is that treatment with some nucleoside analogues causes an imbalance in the levels of the proteins produced by the virus. HBV replication and protein synthesis are normally closely regulated through a number of positive and negative feedback loops. Any imbalance in protein levels generated by lamivudine could therefore upset the normal control mechanisms, allowing unhindered viral replication and/or protein synthesis following withdrawal of therapy. A similar effect has been seen in the DHBV model following ganciclovir treatment .
Long-term antiviral therapy
At present chronic HBV infection requires long-term antiviral therapy, since short-term treatment has not been shown to eliminate the virus. In view of this, it is essential that therapies should be well tolerated. Expense, and the risk of development of resistance are other important considerations. Results from clinical uses of famciclovir in herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) and varicella zoster virus (VZV) infections clearly indicate that it is well tolerated. As reported by Boon and colleagues ( Chicago, USA, 11-14 November 1996, Abstract 623), over 5000 patients have received famciclovir in completed clinical trials to date, and famciclovir has been found to have a similar safety profile to that of placebo. Lamivudine also has a favourable toxicity profile, as seen in studies in patients with HIV disease (Eron, 1996; Styrt et al., 1996) and HBV infection (Honkoop et al., 1997) , although 'rebound' ofviral DNA and ALT levels have been reported following discontinuation of therapy.
Information about the development of resistance to famciclovir and lamivudine is available from their use against HSV and HIV infections, respectively. Cases have already been reported in which HIV has developed complete resistance to lamivudine (Schuurman et al., 1995; Wainberg et al., 1995) . Similarly, thymidine kinasedeficient mutants of HSV generated from aciclovir treatment have also been shown in vitro to have low level resistance to penciclovir (Chiou et al., 1995) . Not surprisingly, mutants of HBV which are resistant to lamivudine and famciclovir are now being reported after antiviral therapy with these agents. Molecular studies of these mutants reveal some common themes. For the lamivudine resistant 80 mutants, mutations occur in the catalytic site of the viral DNA polymerase for both HIV (Schuurman et al., 1995; Wainberg et al., 1995) and HBV (Ling et al., 19%; Tipples et al., 1996) . Such mutations mayor may not confer resistance to other nucleoside analogues. In contrast, the mutations seen in the famciclovir resistant variants ofHSV and HBV occur in a different domain of the viral polymerase (Aye et al., 1997) but how these mutations affect sensitivity to subsequent treatment with other nucleoside analogues remains to be determined.
Future developments
The next decade is likely to see further developments and improvements in therapy for patients with hepatitis B, which should help to reduce morbidity and mortality, as well as the prevalence of chronic hepatitis B. Important new developments potentially include the use of combination therapy, the development of new antiviral agents and agents which stimulate an appropriate immune response, and assays to detect the emergence of resistant mutants.
Combination therapy could provide an effective approach to the problems of resistance developing during long-term antiviral therapy. Studies using famciclovir and lamivudine in combination in primary cultures of duck hepatocytes are yielding promising results, with the two agents having an additive effect against DHBV (Colledge et al., 1997) .
The development of a test system to monitor changes in the viral genome would allow the early detection ofviral mutations and the possible development of resistance. This would allow therapy to be altered before resistance had fully developed. Such a system could resemble that developed by Innogenetics (Ghent, Belgium) for genotyping the hepatitis C virus. A similar system is also being evaluated for the detection of resistance mutations in HIV.
Other possible new therapeutic agents include protease inhibitors, anti-sense RNA, immunogens and therapeutic vaccines. The latter are designed to stimulate the immune system of chronic carriers. They comprise a vaccine containing both T cell and B cell epitopes from the virus, together with an agent to stimulate B cell and T cell proliferation. In general, chronic hepatitis B is caused by an inappropriate immune response directed against infected hepatocytes (Thomas, 1988) . The aim of a therapeutic vaccine is to enhance the immune response and eradicate infected hepatocytes.
